Therapeutic fibrin-derived peptides and uses thereof

ABSTRACT

The invention relates to peptides having the general formula (I), or a salt or amide thereof, wherein R 1  and R 2  are either the same or different, wherein R 1  and R 2  are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z 1  is selected from the group consisting of histidine and proline, wherein Z 2  is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids. The invention also relates to methods using the peptides of the present invention in the treatment of inflammation.

CROSS REFERENCE TO RELATED APPLICATION(S)

[0001] The present application is a continuation of International Patent Application No. PCT/AT01/00387, filed Dec. 7, 2001, published in German on Jun. 20, 2002 as International Patent Publication No. WO02/248180, which claims priority to Austrian Application No. AT A 2063/2000, filed Dec. 12, 2000, all of which are incorporated in their entireties herein.

[0002] The peptides or protein according to the invention exhibit the general formula I

[0003] wherein R₁ and R₂, being equal or different, denote hydrogen, a saturated or unsaturated hydrocarbon residue comprising from 1 to 3, in particular up to 10, carbon atoms,

[0004] Z₁ denotes a histidine or proline residue,

[0005] Z₂ denotes an arginine residue, a peptide residue or a protein residue comprising an initial arginine residue, in particular comprising from 2 to 30 amino acids, as well as the salts thereof, and, f.i., also amides, or mixtures with each other and/or with at least one further substance for therapeutic and/or preventive use in human and/or veterinary medicine, whereby in particular only L-amino acids are provided. Sequences of formula I are listed in Table 1.

[0006] The peptides or protein according to the invention exhibit the general formula II

[0007] wherein R₁ and R₂, being equal or different, denote hydrogen, a saturated or unsaturated hydrocarbon residue comprising from 1 to 3, in particular up to 10, carbon atoms,

[0008] Z₁ denotes a histidine or proline residue,

[0009] Arg denotes an arginine,

[0010] Z₃ denotes a proline or valine residue,

[0011] Z₄ denotes a leucine or valine residue,

[0012] Z₅ denotes a protein residue or a peptide residue, in particular comprising from 2 to 30 amino acids, or an alcohol comprising from 1 to 3, in particular up to 10, carbon atoms, or an organic or inorganic base residue, as well as the salts thereof, and, f.i., also amides, or mixtures with each other and/or with at least one further substance for therapeutic and/or preventive use in human and/or veterinary medicine, whereby in particular only L-amino acids are provided. Sequences of formula II are listed in Table 2.

[0013] A peptide or protein according to the invention of the general formula II, wherein Z₅ denotes a peptide residue comprising the following amino acid sequence (SEQ ID NO: 291): Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg

[0014] and Z₁ denotes a histidine residue,

[0015] Arg denotes an arginine residue,

[0016] Z₃ denotes a proline residue,

[0017] Z₄ denotes a leucine residue

[0018] prevents fibrin fragments from depositing on or adhering to the vascular wall. Thus, it is rendered impossible that inflammatory cells are retained at the endothelial cells of the vascular walls of arteries and veins, and such cells are prevented from remaining at the vascular walls, thud being prevented from infiltrating the tissue any further.

[0019] A peptide or protein of the general formula II, wherein Z₅ denotes a peptide residue comprising the following amino acid sequence (SEQ ID NO: 292): Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys

[0020] and Z₁ denotes a proline residue,

[0021] Arg denotes an arginine residue,

[0022] Z₃ denotes a valine residue,

[0023] Z₄ denotes a valine residue

[0024] has the effect of preventing the cells of the peripheral blood from adhering to fibrin or finrin fragments, hence prohibiting their migration in the tissue.

[0025] Peptide Aalpha (SEQ ID NO: 293) corresponds to amino acids 1 to 28 of the alpha chain of the fibrin and is identical to amino acids 17 to 45 of the Aalpha chain of the fibrinogen: Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys

[0026] Peptide Bbeta (SEQ ID NO: 294) corresponds to amino acids 1 to 28 of the beta chain of the fibrin and is identical to amino acids 15 to 43 of the Bbeta chain of the fibrinogen, which exhibits the following sequence: Gly His Arg Pro Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr     Arg

[0027] TABLE 1 Peptides of Formula I: Gly-His/Pro-Arg-Xaa₂-Xaa₂₉ SEQUENCE SEQ ID NO Gly His Arg 1 Gly Pro Arg 2 Gly His Arg Xaa 3 Gly Pro Arg Xaa 4 Gly His Arg Xaa Xaa 5 Gly Pro Arg Xaa Xaa 6 Gly His Arg Xaa Xaa Xaa 7 Gly Pro Arg Xaa Xaa Xaa 8 Gly His Arg Xaa Xaa Xaa Xaa 9 Gly Pro Arg Xaa Xaa Xaa Xaa 10 Gly His Arg Xaa Xaa Xaa Xaa Xaa 11 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa 12 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa 13 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa 14 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 15 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 16 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 17 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 18 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 19 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 21 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 22 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 23 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 24 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 25 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 26 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 27 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 28 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 29 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 30 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 31 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 32 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 33 Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 34 Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 35 Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 36 Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 37 Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 38 Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 39 Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 40 Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 41 Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 42 Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 43 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 44 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 45 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 46 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 47 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 48 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 49 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 50 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 51 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 52 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 53 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 54 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 55 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 56 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 57 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 58 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

[0028] TABLE 2 Peptides of Formula II: Gly-His/Pro-Arg-Pro/Val-Leu/Val-Xaa₂-Xaa₃₀ SEQUENCE SEQ ID NO Gly His Arg Pro Leu Xaa Xaa 59 Gly Pro Arg Pro Leu Xaa Xaa 60 Gly His Arg Val Leu Xaa Xaa 61 Gly Pro Arg Val Leu Xaa Xaa 62 Gly His Arg Pro Val Xaa Xaa 63 Gly Pro Arg Pro Val Xaa Xaa 64 Gly His Arg Val Val Xaa Xaa 65 Gly Pro Arg Val Val Xaa Xaa 66 Gly His Arg Pro Leu Xaa Xaa Xaa 67 Gly Pro Arg Pro Leu Xaa Xaa Xaa 68 Gly His Arg Val Leu Xaa Xaa Xaa 69 Gly Pro Arg Val Leu Xaa Xaa Xaa 70 Gly His Arg Pro Val Xaa Xaa Xaa 71 Gly Pro Arg Pro Val Xaa Xaa Xaa 72 Gly His Arg Val Val Xaa Xaa Xaa 73 Gly Pro Arg Val Val Xaa Xaa Xaa 74 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa 75 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa 76 Gly His Arg Val Leu Xaa Xaa Xaa Xaa 77 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa 78 Gly His Arg Pro Val Xaa Xaa Xaa Xaa 79 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa 80 Gly His Arg Val Val Xaa Xaa Xaa Xaa 81 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa 82 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa 83 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa 84 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa 85 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa 86 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa 87 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa 88 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa 89 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa 90 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa 91 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa 92 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa 93 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa 94 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa 95 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa 96 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa 97 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa 98 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 99 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 100 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 101 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 102 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 103 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 104 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 105 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 106 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 107 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 108 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 109 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 110 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 111 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 112 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 113 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 114 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 115 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 116 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 117 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 118 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 119 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 120 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 121 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 122 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 123 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 124 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 125 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 126 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 127 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 128 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 129 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 130 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 131 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 132 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 133 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 134 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 135 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 136 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 137 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 138 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 139 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 140 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 141 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 142 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 143 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 144 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 145 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 146 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 147 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 148 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 149 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 150 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 151 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 152 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 153 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 154 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 155 Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 156 Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 157 Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 158 Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 159 Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 160 Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 161 Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 162 Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 163 Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 164 Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 165 Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 166 Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 167 Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 168 Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 169 Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 170 Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 171 Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 172 Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 173 Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 174 Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 175 Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 176 Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 177 Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 178 Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 179 Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 180 Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 181 Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 182 Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 183 Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 184 Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 185 Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 186 Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 187 Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 188 Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 189 Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 190 Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 191 Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 192 Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 193 Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 194 Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 195 Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 196 Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 197 Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 198 Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 199 Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 200 Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 201 Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 202 Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 203 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 204 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 205 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 206 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 207 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 208 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 209 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 210 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 211 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 212 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 213 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 214 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 215 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 216 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 217 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 218 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 219 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 220 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 221 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 222 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 223 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 224 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 225 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 226 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 227 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 228 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 229 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 230 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 231 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 232 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 233 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 234 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 235 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 236 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 237 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 238 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 239 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 240 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 241 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 242 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 243 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 244 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 245 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 246 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 247 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 248 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 249 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 250 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 251 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 252 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 253 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 254 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 255 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 256 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 257 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 258 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 259 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 260 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 261 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 262 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 263 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 264 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 265 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 266 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 267 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 268 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 269 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 270 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 271 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 272 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 273 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 274 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 275 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 276 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 277 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 278 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 279 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 280 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 281 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 282 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 283 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 284 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 285 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 286 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 287 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 288 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 289 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 290 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa

[0029]

1 296 1 3 PRT Artificial Sequence peptide of formula I 1 Gly His Arg 1 2 3 PRT Artificial Sequence peptide of formula I 2 Gly Pro Arg 1 3 4 PRT Artificial Sequence peptide of formula I 3 Gly His Arg Xaa 1 4 4 PRT Artificial Sequence peptide of formula I 4 Gly Pro Arg Xaa 1 5 5 PRT Artificial Sequence peptide of formula I 5 Gly His Arg Xaa Xaa 1 5 6 5 PRT Artificial Sequence peptide of formula I 6 Gly Pro Arg Xaa Xaa 1 5 7 6 PRT Artificial Sequence peptide of formula I 7 Gly His Arg Xaa Xaa Xaa 1 5 8 6 PRT Artificial Sequence peptide of formula I 8 Gly Pro Arg Xaa Xaa Xaa 1 5 9 7 PRT Artificial Sequence peptide of formula I 9 Gly His Arg Xaa Xaa Xaa Xaa 1 5 10 7 PRT Artificial Sequence peptide of formula I 10 Gly Pro Arg Xaa Xaa Xaa Xaa 1 5 11 8 PRT Artificial Sequence peptide of formula I 11 Gly His Arg Xaa Xaa Xaa Xaa Xaa 1 5 12 8 PRT Artificial Sequence peptide of formula I 12 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa 1 5 13 9 PRT Artificial Sequence peptide of formula I 13 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa 1 5 14 9 PRT Artificial Sequence peptide of formula I 14 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa 1 5 15 10 PRT Artificial Sequence peptide of formula I 15 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 16 10 PRT Artificial Sequence peptide of formula I 16 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 17 11 PRT Artificial Sequence peptide of formula I 17 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 18 11 PRT Artificial Sequence peptide of formula I 18 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 19 12 PRT Artificial Sequence peptide of formula I 19 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 20 12 PRT Artificial Sequence peptide of formula I 20 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 21 13 PRT Artificial Sequence peptide of formula I 21 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 22 13 PRT Artificial Sequence peptide of formula I 22 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 23 14 PRT Artificial Sequence peptide of formula I 23 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 24 14 PRT Artificial Sequence peptide of formula I 24 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 25 15 PRT Artificial Sequence peptide of formula I 25 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 26 15 PRT Artificial Sequence peptide of formula I 26 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 27 16 PRT Artificial Sequence peptide of formula I 27 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 28 16 PRT Artificial Sequence peptide of formula I 28 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 29 17 PRT Artificial Sequence peptide of formula I 29 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 30 17 PRT Artificial Sequence peptide of formula I 30 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 31 18 PRT Artificial Sequence peptide of formula I 31 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 32 18 PRT Artificial Sequence peptide of formula I 32 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 33 20 PRT Artificial Sequence peptide of formula I 33 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 34 20 PRT Artificial Sequence peptide of formula I 34 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 35 21 PRT Artificial Sequence peptide of formula I 35 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 36 21 PRT Artificial Sequence peptide of formula I 36 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 37 22 PRT Artificial Sequence peptide of formula I 37 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 38 22 PRT Artificial Sequence peptide of formula I 38 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 39 23 PRT Artificial Sequence peptide of formula I 39 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 40 23 PRT Artificial Sequence peptide of formula I 40 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 41 24 PRT Artificial Sequence peptide of formula I 41 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 42 24 PRT Artificial Sequence peptide of formula I 42 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 43 25 PRT Artificial Sequence peptide of formula I 43 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 44 25 PRT Artificial Sequence peptide of formula I 44 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 45 26 PRT Artificial Sequence peptide of formula I 45 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 46 26 PRT Artificial Sequence peptide of formula I 46 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 47 27 PRT Artificial Sequence peptide of formula I 47 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 48 27 PRT Artificial Sequence peptide of formula I 48 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 49 28 PRT Artificial Sequence peptide of formula I 49 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 50 28 PRT Artificial Sequence peptide of formula I 50 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 51 29 PRT Artificial Sequence peptide of formula I 51 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 52 29 PRT Artificial Sequence peptide of formula I 52 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 53 30 PRT Artificial Sequence peptide of formula I 53 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 54 30 PRT Artificial Sequence peptide of formula I 54 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 55 31 PRT Artificial Sequence peptide of formula I 55 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 56 31 PRT Artificial Sequence peptide of formula I 56 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 57 32 PRT Artificial Sequence peptide of formula I 57 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 58 32 PRT Artificial Sequence peptide of formula I 58 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 59 7 PRT Artificial Sequence peptide of formula II 59 Gly His Arg Pro Leu Xaa Xaa 1 5 60 7 PRT Artificial Sequence peptide of formula II 60 Gly Pro Arg Pro Leu Xaa Xaa 1 5 61 7 PRT Artificial Sequence peptide of formula II 61 Gly His Arg Val Leu Xaa Xaa 1 5 62 7 PRT Artificial Sequence peptide of formula II 62 Gly Pro Arg Val Leu Xaa Xaa 1 5 63 7 PRT Artificial Sequence peptide of formula II 63 Gly His Arg Pro Val Xaa Xaa 1 5 64 7 PRT Artificial Sequence peptide of formula II 64 Gly Pro Arg Pro Val Xaa Xaa 1 5 65 7 PRT Artificial Sequence peptide of formula II 65 Gly His Arg Val Val Xaa Xaa 1 5 66 7 PRT Artificial Sequence peptide of formula II 66 Gly Pro Arg Val Val Xaa Xaa 1 5 67 8 PRT Artificial Sequence peptide of formula II 67 Gly His Arg Pro Leu Xaa Xaa Xaa 1 5 68 8 PRT Artificial Sequence peptide of formula II 68 Gly Pro Arg Pro Leu Xaa Xaa Xaa 1 5 69 8 PRT Artificial Sequence peptide of formula II 69 Gly His Arg Val Leu Xaa Xaa Xaa 1 5 70 8 PRT Artificial Sequence peptide of formula II 70 Gly Pro Arg Val Leu Xaa Xaa Xaa 1 5 71 8 PRT Artificial Sequence peptide of formula II 71 Gly His Arg Pro Val Xaa Xaa Xaa 1 5 72 8 PRT Artificial Sequence peptide of formula II 72 Gly Pro Arg Pro Val Xaa Xaa Xaa 1 5 73 8 PRT Artificial Sequence peptide of formula II 73 Gly His Arg Val Val Xaa Xaa Xaa 1 5 74 8 PRT Artificial Sequence peptide of formula II 74 Gly Pro Arg Val Val Xaa Xaa Xaa 1 5 75 9 PRT Artificial Sequence peptide of formula II 75 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa 1 5 76 9 PRT Artificial Sequence peptide of formula II 76 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa 1 5 77 9 PRT Artificial Sequence peptide of formula II 77 Gly His Arg Val Leu Xaa Xaa Xaa Xaa 1 5 78 9 PRT Artificial Sequence peptide of formula II 78 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa 1 5 79 9 PRT Artificial Sequence peptide of formula II 79 Gly His Arg Pro Val Xaa Xaa Xaa Xaa 1 5 80 9 PRT Artificial Sequence peptide of formula II 80 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa 1 5 81 9 PRT Artificial Sequence peptide of formula II 81 Gly His Arg Val Val Xaa Xaa Xaa Xaa 1 5 82 9 PRT Artificial Sequence peptide of formula II 82 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa 1 5 83 10 PRT Artificial Sequence peptide of formula II 83 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa 1 5 10 84 10 PRT Artificial Sequence peptide of formula II 84 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa 1 5 10 85 10 PRT Artificial Sequence peptide of formula II 85 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa 1 5 10 86 10 PRT Artificial Sequence peptide of formula II 86 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa 1 5 10 87 10 PRT Artificial Sequence peptide of formula II 87 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa 1 5 10 88 10 PRT Artificial Sequence peptide of formula II 88 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa 1 5 10 89 10 PRT Artificial Sequence peptide of formula II 89 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa 1 5 10 90 10 PRT Artificial Sequence peptide of formula II 90 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa 1 5 10 91 11 PRT Artificial Sequence peptide of formula II 91 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 92 11 PRT Artificial Sequence peptide of formula II 92 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 93 11 PRT Artificial Sequence peptide of formula II 93 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 94 11 PRT Artificial Sequence peptide of formula II 94 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 95 11 PRT Artificial Sequence peptide of formula II 95 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 96 11 PRT Artificial Sequence peptide of formula II 96 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 97 11 PRT Artificial Sequence peptide of formula II 97 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 98 11 PRT Artificial Sequence peptide of formula II 98 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 99 12 PRT Artificial Sequence peptide of formula II 99 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 100 12 PRT Artificial Sequence peptide of formula II 100 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 101 12 PRT Artificial Sequence peptide of formula II 101 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 102 12 PRT Artificial Sequence peptide of formula II 102 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 103 12 PRT Artificial Sequence peptide of formula II 103 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 104 12 PRT Artificial Sequence peptide of formula II 104 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 105 12 PRT Artificial Sequence peptide of formula II 105 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 106 12 PRT Artificial Sequence peptide of formula II 106 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 107 13 PRT Artificial Sequence peptide of formula II 107 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 108 13 PRT Artificial Sequence peptide of formula II 108 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 109 13 PRT Artificial Sequence peptide of formula II 109 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 110 13 PRT Artificial Sequence peptide of formula II 110 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 111 13 PRT Artificial Sequence peptide of formula II 111 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 112 13 PRT Artificial Sequence peptide of formula II 112 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 113 13 PRT Artificial Sequence peptide of formula II 113 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 114 13 PRT Artificial Sequence peptide of formula II 114 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 115 14 PRT Artificial Sequence peptide of formula II 115 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 116 14 PRT Artificial Sequence peptide of formula II 116 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 117 14 PRT Artificial Sequence peptide of formula II 117 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 118 14 PRT Artificial Sequence peptide of formula II 118 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 119 14 PRT Artificial Sequence peptide of formula II 119 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 120 14 PRT Artificial Sequence peptide of formula II 120 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 121 14 PRT Artificial Sequence peptide of formula II 121 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 122 14 PRT Artificial Sequence peptide of formula II 122 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 123 15 PRT Artificial Sequence peptide of formula II 123 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 124 15 PRT Artificial Sequence peptide of formula II 124 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 125 15 PRT Artificial Sequence peptide of formula II 125 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 126 15 PRT Artificial Sequence peptide of formula II 126 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 127 15 PRT Artificial Sequence Xaa=any amino acid 127 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 128 15 PRT Artificial Sequence peptide of formula II 128 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 129 15 PRT Artificial Sequence peptide of formula II 129 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 130 15 PRT Artificial Sequence peptide of formula II 130 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 131 16 PRT Artificial Sequence peptide of formula II 131 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 132 16 PRT Artificial Sequence peptide of formula II 132 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 133 16 PRT Artificial Sequence peptide of formula II 133 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 134 16 PRT Artificial Sequence peptide of formula II 134 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 135 16 PRT Artificial Sequence peptide of formula II 135 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 136 16 PRT Artificial Sequence peptide of formula II 136 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 137 16 PRT Artificial Sequence peptide of formula II 137 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 138 16 PRT Artificial Sequence peptide of formula II 138 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 139 17 PRT Artificial Sequence peptide of formula II 139 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 140 17 PRT Artificial Sequence peptide of formula II 140 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 141 17 PRT Artificial Sequence peptide of formula II 141 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 142 17 PRT Artificial Sequence peptide of formula II 142 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 143 17 PRT Artificial Sequence peptide of formula II 143 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 144 17 PRT Artificial Sequence peptide of formula II 144 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 145 17 PRT Artificial Sequence peptide of formula II 145 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 146 17 PRT Artificial Sequence peptide of formula II 146 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa 147 18 PRT Artificial Sequence peptide of formula II 147 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 148 18 PRT Artificial Sequence peptide of formula II 148 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 149 18 PRT Artificial Sequence peptide of formula II 149 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 150 18 PRT Artificial Sequence peptide of formula II 150 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 151 18 PRT Artificial Sequence peptide of formula II 151 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 152 18 PRT Artificial Sequence peptide of formula II 152 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 153 18 PRT Artificial Sequence peptide of formula II 153 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 154 18 PRT Artificial Sequence peptide of formula II 154 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa 155 19 PRT Artificial Sequence peptide of formula II 155 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 156 19 PRT Artificial Sequence peptide of formula II 156 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 157 19 PRT Artificial Sequence peptide of formula II 157 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 158 19 PRT Artificial Sequence peptide of formula II 158 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 159 19 PRT Artificial Sequence peptide of formula II 159 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 160 19 PRT Artificial Sequence peptide of formula II 160 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 161 19 PRT Artificial Sequence peptide of formula II 161 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 162 19 PRT Artificial Sequence peptide of formula II 162 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 163 20 PRT Artificial Sequence peptide of formula II 163 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 164 20 PRT Artificial Sequence peptide of formula II 164 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 165 20 PRT Artificial Sequence peptide of formula II 165 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 166 20 PRT Artificial Sequence peptide of formula II 166 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 167 20 PRT Artificial Sequence peptide of formula II 167 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 168 20 PRT Artificial Sequence peptide of formula II 168 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 169 20 PRT Artificial Sequence peptide of formula II 169 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 170 20 PRT Artificial Sequence peptide of formula II 170 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa 20 171 21 PRT Artificial Sequence peptide of formula II 171 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 172 21 PRT Artificial Sequence peptide of formula II 172 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 173 21 PRT Artificial Sequence peptide of formula II 173 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 174 21 PRT Artificial Sequence peptide of formula II 174 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 175 21 PRT Artificial Sequence peptide of formula II 175 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 176 21 PRT Artificial Sequence peptide of formula II 176 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 177 21 PRT Artificial Sequence peptide of formula II 177 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 178 21 PRT Artificial Sequence peptide of formula II 178 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa 20 179 22 PRT Artificial Sequence peptide of formula II 179 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 180 22 PRT Artificial Sequence peptide of formula II 180 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 181 22 PRT Artificial Sequence peptide of formula II 181 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 182 22 PRT Artificial Sequence peptide of formula II 182 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 183 22 PRT Artificial Sequence peptide of formula II 183 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 184 22 PRT Artificial Sequence peptide of formula II 184 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 185 22 PRT Artificial Sequence peptide of formula II 185 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 186 22 PRT Artificial Sequence peptide of formula II 186 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa 20 187 23 PRT Artificial Sequence peptide of formula II 187 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 188 23 PRT Artificial Sequence peptide of formula II 188 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 189 23 PRT Artificial Sequence peptide of formula II 189 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 190 23 PRT Artificial Sequence peptide of formula II 190 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 191 23 PRT Artificial Sequence peptide of formula II 191 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 192 23 PRT Artificial Sequence peptide of formula II 192 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 193 23 PRT Artificial Sequence peptide of formula II 193 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 194 23 PRT Artificial Sequence peptide of formula II 194 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 195 24 PRT Artificial Sequence peptide of formula II 195 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 196 24 PRT Artificial Sequence peptide of formula II 196 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 197 24 PRT Artificial Sequence peptide of formula II 197 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 198 24 PRT Artificial Sequence peptide of formula II 198 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 199 24 PRT Artificial Sequence peptide of formula II 199 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 200 24 PRT Artificial Sequence peptide of formula II 200 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 201 24 PRT Artificial Sequence peptide of formula II 201 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 202 24 PRT Artificial Sequence peptide of formula II 202 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 203 25 PRT Artificial Sequence peptide of formula II 203 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 204 25 PRT Artificial Sequence peptide of formula II 204 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 205 25 PRT Artificial Sequence peptide of formula II 205 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 206 25 PRT Artificial Sequence peptide of formula II 206 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 207 25 PRT Artificial Sequence peptide of formula II 207 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 208 25 PRT Artificial Sequence peptide of formula II 208 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 209 25 PRT Artificial Sequence peptide of formula II 209 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 210 25 PRT Artificial Sequence peptide of formula II 210 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 211 26 PRT Artificial Sequence peptide of formula II 211 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 212 26 PRT Artificial Sequence peptide of formula II 212 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 213 26 PRT Artificial Sequence peptide of formula II 213 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 214 26 PRT Artificial Sequence peptide of formula II 214 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 215 26 PRT Artificial Sequence peptide of formula II 215 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 216 26 PRT Artificial Sequence peptide of formula II 216 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 217 26 PRT Artificial Sequence peptide of formula II 217 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 218 26 PRT Artificial Sequence peptide of formula II 218 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 219 27 PRT Artificial Sequence peptide of formula II 219 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 220 27 PRT Artificial Sequence peptide of formula II 220 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 221 27 PRT Artificial Sequence peptide of formula II 221 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 222 27 PRT Artificial Sequence peptide of formula II 222 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 223 27 PRT Artificial Sequence peptide of formula II 223 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 224 27 PRT Artificial Sequence peptide of formula II 224 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 225 27 PRT Artificial Sequence peptide of formula II 225 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 226 27 PRT Artificial Sequence peptide of formula II 226 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 227 28 PRT Artificial Sequence peptide of formula II 227 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 228 28 PRT Artificial Sequence peptide of formula II 228 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 229 28 PRT Artificial Sequence peptide of formula II 229 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 230 28 PRT Artificial Sequence peptide of formula II 230 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 231 28 PRT Artificial Sequence peptide of formula II 231 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 232 28 PRT Artificial Sequence peptide of formula II 232 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 233 28 PRT Artificial Sequence peptide of formula II 233 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 234 28 PRT Artificial Sequence peptide of formula II 234 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 235 29 PRT Artificial Sequence peptide of formula II 235 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 236 29 PRT Artificial Sequence peptide of formula II 236 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 237 29 PRT Artificial Sequence peptide of formula II 237 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 238 29 PRT Artificial Sequence peptide of formula II 238 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 239 29 PRT Artificial Sequence peptide of formula II 239 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 240 29 PRT Artificial Sequence peptide of formula II 240 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 241 29 PRT Artificial Sequence peptide of formula II 241 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 242 29 PRT Artificial Sequence peptide of formula II 242 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 243 30 PRT Artificial Sequence peptide of formula II 243 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 244 30 PRT Artificial Sequence peptide of formula II 244 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 245 30 PRT Artificial Sequence peptide of formula II 245 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 246 30 PRT Artificial Sequence peptide of formula II 246 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 247 30 PRT Artificial Sequence peptide of formula II 247 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 248 30 PRT Artificial Sequence peptide of formula II 248 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 249 30 PRT Artificial Sequence peptide of formula II 249 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 250 30 PRT Artificial Sequence peptide of formula II 250 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 251 31 PRT Artificial Sequence peptide of formula II 251 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 252 31 PRT Artificial Sequence peptide of formula II 252 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 253 31 PRT Artificial Sequence peptide of formula II 253 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 254 31 PRT Artificial Sequence peptide of formula II Xaa=any amino acid 254 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 255 31 PRT Artificial Sequence peptide of formula II 255 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 256 31 PRT Artificial Sequence peptide of formula II 256 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 257 31 PRT Artificial Sequence peptide of formula II 257 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 258 31 PRT Artificial Sequence peptide of formula II 258 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 259 32 PRT Artificial Sequence peptide of formula II 259 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 260 32 PRT Artificial Sequence peptide of formula II 260 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 261 32 PRT Artificial Sequence peptide of formula II 261 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 262 32 PRT Artificial Sequence peptide of formula II 262 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 263 32 PRT Artificial Sequence peptide of formula II 263 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 264 32 PRT Artificial Sequence peptide of formula II 264 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 265 32 PRT Artificial Sequence peptide of formula II 265 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 266 32 PRT Artificial Sequence peptide of formula II 266 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 267 33 PRT Artificial Sequence peptide of formula II 267 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa 268 33 PRT Artificial Sequence peptide of formula II 268 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa 269 33 PRT Artificial Sequence peptide of formula II 269 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa 270 33 PRT Artificial Sequence peptide of formula II 270 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa 271 33 PRT Artificial Sequence peptide of formula II 271 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa 272 33 PRT Artificial Sequence peptide of formula II 272 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa 273 33 PRT Artificial Sequence peptide of formula II 273 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa 274 33 PRT Artificial Sequence peptide of formula II 274 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa 275 34 PRT Artificial Sequence peptide of formula II 275 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa 276 34 PRT Artificial Sequence peptide of formula II 276 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa 277 34 PRT Artificial Sequence peptide of formula II 277 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa 278 34 PRT Artificial Sequence peptide of formula II 278 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa 279 34 PRT Artificial Sequence peptide of formula II 279 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa 280 34 PRT Artificial Sequence peptide of formula II 280 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa 281 34 PRT Artificial Sequence peptide of formula II 281 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa 282 34 PRT Artificial Sequence peptide of formula II 282 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa 283 35 PRT Artificial Sequence peptide of formula II 283 Gly His Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa 35 284 35 PRT Artificial Sequence peptide of formula II 284 Gly Pro Arg Pro Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa 35 285 35 PRT Artificial Sequence peptide of formula II 285 Gly His Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa 35 286 35 PRT Artificial Sequence peptide of formula II 286 Gly Pro Arg Val Leu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa 35 287 35 PRT Artificial Sequence peptide of formula II 287 Gly His Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa 35 288 35 PRT Artificial Sequence peptide of formula II 288 Gly Pro Arg Pro Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa 35 289 35 PRT Artificial Sequence peptide of formula II 289 Gly His Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa 35 290 35 PRT Artificial Sequence peptide of formula II 290 Gly Pro Arg Val Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 20 25 30 Xaa Xaa Xaa 35 291 23 PRT Artificial Sequence peptide of formula II 291 Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro 1 5 10 15 Ile Ser Gly Gly Gly Tyr Arg 20 292 23 PRT Artificial Sequence peptide of formula II 292 Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser 1 5 10 15 Asp Glu Asp Trp Asn Tyr Lys 20 293 28 PRT Artificial Sequence peptide Aalpha 293 Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp 1 5 10 15 Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys 20 25 294 28 PRT Artificial Sequence peptide Bbeta 294 Gly His Arg Pro Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg 1 5 10 15 Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg 20 25 295 19 PRT Artificial Sequence peptide of formula I 295 Gly His Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 296 19 PRT Artificial Sequence peptide of formula I 296 Gly Pro Arg Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa 1 5 10 15 Xaa Xaa Xaa 

1. A method of treating inflammation in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 2. The method of claim 1, wherein the peptide, or salt or amide thereof, comprises a peptide derived from the Aalpha-chain of fibrin.
 3. The method of claim 1, wherein the peptide, or salt or amide thereof, comprises a peptide derived from the Bbeta-chain of fibrin.
 4. A method of treating inflammation in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 5. The method of claim 4, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


6. The method of claim 5, wherein Z₁ is histidine, Z₃ is proline, and Z₄ is leucine.
 7. The method of claim 6, wherein the peptide, or salt or amide thereof comprises the amino acid sequence (SEQ ID NO: 294): Gly His Arg Pro Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


8. The method of claim 4, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


9. The method of claim 8, wherein Z₁ is proline, Z₃ is valine, and Z₄ is valine.
 10. The method of claim 9, wherein the peptide, salt or amide thereof comprises the amino acid sequence (SEQ ID NO: 293): Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


11. A method of preventing inflammation in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 12. The method of claim 11, wherein the peptide, or salt or amide thereof, comprises a peptide derived from the Aalpha-chain of fibrin.
 13. The method of claim 11, wherein the peptide, or salt or amide thereof, comprises a peptide derived from the Bbeta-chain of fibrin.
 14. A method of preventing inflammation in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 15. The method of claim 14, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


16. The method of claim 15, wherein Z₁ is histidine, Z₃ is proline, and Z₄ is leucine.
 17. The method of claim 16, wherein the peptide, or salt or amide thereof comprises the amino acid sequence (SEQ ID NO: 294): Gly His Arg Pro Leu Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


18. The method of claim 14, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


19. The method of claim 18, wherein Z₁ is proline, Z₃ is valine, and Z₄ is valine.
 20. The method of claim 19, wherein the peptide, salt or amide thereof comprises the amino acid sequence (SEQ ID NO: 293): Gly Pro Arg Val Val Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


21. The method of claim 1, 4, 11 or 14, wherein the inflammation is due to a condition selected from the group consisting of an infection, an autoimmune condition, a rheumatic disorder, or a disorder of the immune system.
 22. A method of treating rejection of a transplanted tissue in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 23. The method of claim 22, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 24. A method of treating rejection of a transplanted tissue in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 25. The method of claim 24, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


26. The method of claim 4, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


27. A method of preventing rejection of a transplanted tissue in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 28. The method of claim 27, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 29. A method of preventing rejection of a transplanted tissue in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 30. The method of claim 29, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


31. The method of claim 29, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


32. A method of treating arterial sclerosis in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 33. The method of claim 32, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 34. A method of treating arterial sclerosis in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 35. The method of claim 34, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu +TL,32 Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


36. The method of claim 34, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


37. A method of preventing arterial sclerosis in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 38. The method of claim 37, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 39. A method of preventing arterial sclerosis in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 40. The method of claim 39, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


41. The method of claim 39, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


42. The method of claim 32, 34, 37 or 39 wherein arterial sclerosis is treated or prevented in a transplanted tissue in a subject.
 43. A method of treating reperfusion injury in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 44. The method of claim 43, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 45. A method of treating reperfusion injury in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 46. The method of claim 45, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


47. The method of claim 45, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


48. A method of preventing reperfusion injury in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 49. The method of claim 48, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 50. A method of preventing reperfusion injury in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 51. The method of claim 50, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


52. The method of claim 50, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


53. A method of treating thrombotic disease in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 54. The method of claim 54, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 55. A method of treating thrombotic disease in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 56. The method of claim 55, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


57. The method of claim 55, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


58. A method of preventing thrombotic disease in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 59. The method of claim 58, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 60. A method of preventing thrombotic disease in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 61. The method of claim 60, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


62. The method of claim 60, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292, Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys.


63. A method of preventing fibrin fragments from adhering to a vascular wall of a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 64. The method of claim 63, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from the Bbeta chain of fibrin.
 65. A method of preventing fibrin fragments from adhering to a vascular wall of a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof, wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 66. The method of claim 39, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


67. A method of transporting a drug substance to a cell in a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids, and wherein the drug substance is coupled to said peptide.
 68. A method of transporting a drug substance to a cell in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base, and wherein the drug substance is coupled to said peptide.
 69. The method of claim 39, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


70. A method of inhibiting adhesion of cells in the bloodstream to endothelial cells of the vascular wall of a subject comprising administering to the subject an effective amount of a peptide having the general formula (I),

or a salt or amide thereof wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Z₂ is selected from the group consisting of an arginine and a peptide comprising an initial arginine and having from 2 to 30 amino acids.
 71. The method of claim 70, wherein the peptide, or a salt or amide thereof, comprises a peptide derived from a source selected from the group consisting of the Aalpha-chain of fibrin and the Bbeta chain of fibrin.
 72. A method of inhibiting adhesion of cells in the bloodstream to endothelial cells of the vascular wall of a subject in a subject comprising administering to the subject an effective amount of a peptide having the general formula (II),

or a salt or amide thereof; wherein R₁ and R₂ are either the same or different, wherein R₁ and R₂ are each selected from the group consisting of hydrogen and a saturated or unsaturated hydrocarbon residue, said residue having from 1 to 10 carbon atoms, wherein Z₁ is selected from the group consisting of histidine and proline, wherein Arg is arginine, wherein Z₃ is selected from the group consisting of proline and valine, wherein Z₄ is selected from the group consisting of leucine and valine, wherein Z₅ is selected from the group consisting of a peptide having from 2 to 30 amino acids, an alcohol having from 1 to 10 carbon atoms, and an organic or inorganic base.
 73. The method of claim 72, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:291, Asp Lys Lys Arg Glu Glu Ala Pro Ser Leu Arg Pro Ala Pro Pro Pro Ile Ser Gly Gly Gly Tyr Arg.


74. The method of claim 72, wherein Z₅ is a peptide comprising an amino acid sequence set forth in SEQ ID NO:292,     Glu Arg His Gln Ser Ala Cys Lys Asp Ser Asp Trp Pro Phe Cys Ser Asp Glu Asp Trp Asn Tyr Lys. 